|Outcome||Comparison||Number of trials (n)||RRR (95% CI)|
|*ICSs = inhaled corticosteroids; SABAs = short acting β2 agonists; LABAs = long acting β2 agonists; LPMs/RAs = leukotriene pathway modifiers/receptor antagonists. Other abbreviations defined in glossary; RRR and CI calculated from data in article.|
|†Calculated using a random effects model.|
|Rate of exacerbations||ICSs v placebo or SABAs||11 (9418)||54% (38 to 66)†|
|LABAs v placebo||9 (2854)||25% (12 to 36)|
|ICSs plus LABAs v ICSs||7 (3886)||26% (9 to 39)|
|ICSs plus LABAs v doubled dosage of ICSs||10 (5680)||14% (4 to 24)|
|LPMs/RAs v placebo||7 (4375)||41% (29 to 51)|
|ICSs plus anti-IgE antibodies v ICSs||3 (1388)||45% (34 to 55)|
Review: long term use of common medications for asthma reduces exacerbations in adults
EBN Twitter Journal Club
The club runs like other journal discussion groups, except that the article and questions are posted on this blog and
the discussion about the article happens on Twitter.
How to participate >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.